The first formal meeting with FDA yielded positive feedback to Oncology Venture. The Danish biotech company aims to obtain US approval of its breast cancer candidate and expects to file an application for initiating phase III trialsduring first half of 2019.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.